Track record · closed signal

Danaher Corporation (DHR) — closed signal from October 21, 2025

Partial Published before the outcome was known, scored automatically when the window closed on January 19, 2026.

Predicted vs. what happened

DHR price · publication thesis → realized outcomesplit-adjusted
$224.61 Published $257.95 Target $235.99 Window close $241.26 Peak
$221.39 – $225.38Entry zone — fair-value band
$224.61Published — price the day we called it
$257.95Target — the price the thesis aimed for
$241.26Peak — highest point inside the window, not a realized return
$235.99Window close — end-of-window price, context only

What happened

Partial

Reached 49% of the predicted growth at its peak, without hitting the target.

Peak price
$241.26
peak on January 13, 2026 — not a realized return
Peak gain
+7.4%
peak, from the publication price
Window close
$235.99
end-of-window price, context only
Days to target
—
Window
October 21, 2025 – January 19, 2026

The thesis — published October 21, 2025

Predicted growth
+15%
over the measurement window
Target price
$257.95
the price the thesis aimed for
Entry zone
$221.39 – $225.38
the fair-value band we waited for
Price at publication
$224.61
published October 21, 2025
Confidence
66%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Danaher beat expectations and grew sales 4.4%. The price trend is improving, and more buyers than usual have been active on up days. In a friendly earnings season, its high-quality lab tools can attract fresh money from funds. Buying near recent price lows aims for a steady move over the next 0-3 months toward past highs, while risk stays measured. This balances some mixed backward-looking metrics as momentum rebuilds.

Primary drivers

  • Latest quarter beat expectations; sales grew 4.4% versus last year
  • Trend improving with strong recent average price and constructive action
  • More buyers than usual on up days, showing healthy demand for shares
  • High-quality lab and diagnostic tools can draw new money from investors

How it played out

DHR: target was not reached by window end

Lyra published DHR on 2025-10-21 at $224.61, with an expected 15% gain toward $257.95 over the short-term window. The thesis pointed to a quarter that beat expectations, 4.4% sales growth versus last year, an improving price trend, stronger buying on up days, and demand for high-quality lab and diagnostic tools.

Inside the window, DHR rose but did not reach the target. The peak was $241.26 on 2026-01-13, a 7.4% gain. It ended the window at $235.99 on 2026-01-19. The thesis partially played out on direction, but it missed the published target. It never got there.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All DHR signals